Summary & Overview
HCPCS J1725: Injection, Hydroxyprogesterone Caproate, 1 mg
HCPCS Level II code J1725 denotes the injection of hydroxyprogesterone caproate, 1 mg, a progestin formulation used in obstetric care. Nationally, this code is important for tracking utilization of injectable progestogen therapy and for payer reimbursement of medication administration in outpatient settings. It is relevant to clinicians, billing teams, and policy analysts because medication-specific HCPCS codes affect coverage determinations, claim processing, and aggregate spending measures.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1725, how the service is typically delivered, and the payer landscape influencing coverage and billing. The publication provides benchmarks and comparisons where available, summarizes any notable policy updates that affect coding and payment for injectable medications, and highlights common billing considerations tied to outpatient administration of hydroxyprogesterone caproate.
This summary is intended for a national audience and focuses on what the code represents, typical sites of service, and the payer coverage environment, enabling billing professionals and clinicians to contextualize J1725 within clinical and administrative workflows.
Billing Code Overview
HCPCS Level II code J1725 represents an injection of hydroxyprogesterone caproate, 1 mg. This code is used to report administration of the medication as a pharmaceutical supply intended for therapeutic use. The service type is medication administration/pharmacologic therapy, and the typical site of service is outpatient clinic or ambulatory care settings where injectable therapies are provided, including obstetrics clinics and infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pregnant person with a singleton pregnancy and a history of spontaneous preterm delivery between 20 0/7 and 36 6/7 weeks in a prior pregnancy. At a prenatal visit between 16 and 24 weeks' gestation the obstetric clinician discusses and administers intramuscular J1725 (hydroxyprogesterone caproate) as a weekly injection to reduce the risk of recurrent preterm birth. The workflow includes verification of gestational age and prior obstetric history, informed consent, medication preparation (dosing by weight per product labeling), intramuscular administration (usually in the gluteal muscle), monitoring for immediate adverse reaction for 15–30 minutes, documentation of lot number and injection site, and scheduling of subsequent weekly injections until 36 6/7 weeks' gestation or delivery. Nursing documents medication administration in the chart and notifies the prescribing provider of any injection site reactions, allergic signs, or unexpected symptoms. Prior authorization may be obtained from payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, or Medicare when required; billing uses HCPCS code J1725 for the drug per milligram units and may include appropriate modifiers for site, billing indicator, or administrative circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug quantity discarded/not administered |